| Company Name: |
Energy Chemical
|
| Tel: |
021-58432009 400-005-6266 |
| Email: |
marketing1@energy-chemical.com |
| Products Intro: |
Product Name:LY255582 >=98% (HPLC)
CAS:119193-09-8
Purity:NULL Package:25mg;5mg Remarks:NULL
|
| Company Name: |
Merck KGaA
|
| Tel: |
21-20338288 |
| Email: |
ordercn@merckgroup.com |
| Products Intro: |
Product Name:LY255582
CAS:119193-09-8
|
| Company Name: |
Riedel-de Haen AG
|
| Tel: |
800 558-9160 |
| Email: |
|
| Products Intro: |
Product Name:LY255582
CAS:119193-09-8
|
|
| | 3-[1-[(S)-3-Hydroxy-3-cyclohexylpropyl]-3α,4-dimethylpiperidine-4α-yl]phenol Basic information |
| Product Name: | 3-[1-[(S)-3-Hydroxy-3-cyclohexylpropyl]-3α,4-dimethylpiperidine-4α-yl]phenol | | Synonyms: | (+)-3-[(3R,4R)-1-[(S)-3-Hydroxy-3-cyclohexylpropyl]-3,4-dimethylpiperidin-4-yl]phenol;3-[1-[(S)-3-Hydroxy-3-cyclohexylpropyl]-3α,4-dimethylpiperidine-4α-yl]phenol;LY-255582;(3R,4R)-3,4-Dimethyl-1-[(3S)-3-hydroxy-3-cyclohexyl-propyl]-4-(3-hydroxyphenyl)piperidine;(aS,3R,4R)-a-Cyclohexyl-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinepropanol;LY255582 >=98% (HPLC);1-Piperidinepropanol, α-cyclohexyl-4-(3-hydroxyphenyl)-3,4-dimethyl-, (αS,3R,4R)- | | CAS: | 119193-09-8 | | MF: | C22H35NO2 | | MW: | 345.52 | | EINECS: | | | Product Categories: | | | Mol File: | 119193-09-8.mol | ![3-[1-[(S)-3-Hydroxy-3-cyclohexylpropyl]-3α,4-dimethylpiperidine-4α-yl]phenol Structure](CAS/20180713/GIF/119193-09-8.gif) |
| | 3-[1-[(S)-3-Hydroxy-3-cyclohexylpropyl]-3α,4-dimethylpiperidine-4α-yl]phenol Chemical Properties |
| Melting point | 154-155 °C | | Boiling point | 502.3±50.0 °C(Predicted) | | density | 1.045±0.06 g/cm3(Predicted) | | storage temp. | 2-8°C | | solubility | DMSO: ≥15mg/mL | | pka | 9.96±0.10(Predicted) | | form | powder | | color | white to beige |
| | 3-[1-[(S)-3-Hydroxy-3-cyclohexylpropyl]-3α,4-dimethylpiperidine-4α-yl]phenol Usage And Synthesis |
| Uses | LY255582 may be used in opioid receptor-mediated cell signaling studies. | | Biological Activity | LY255582 inhibits the diet-associated increases in mesolimbic dopamine levels and reduces the consumption of highly-palatable food intake.', 'LY255582 is a centrally active opioid receptor antagonist (defined as an inverse agonist in 2011 JPET paper) th at inhibited weight gain in obese Zucker rats over 30 days. It is more th at 5-fold selective for mu opioid receptor compared to kappa opioid receptors and 13-fold selective over delta opioid receptors. | | in vivo | LY255582 (100 μg, i.c.v.) reduced food intake in rats[1].
LY255582 (15 mg/kg, s.c., once daily) decreases food intake and body weight gain of fed obese Zucker rats[4].
| Animal Model: | STZ-induced diabetic mice[1] | | Dosage: | 100, 10 and 1 μg | | Administration: | i.c.v. | | Result: | Decreased food at 100, 10 and 1 μg by 76, 62 and 29%. |
| | IC 50 | μ Opioid Receptor/MOR: 0.4 nM (Ki); δ Opioid Receptor/DOR: 5.2 nM (Ki); κ Opioid Receptor/KOR: 2.0 nM (Ki) |
| | 3-[1-[(S)-3-Hydroxy-3-cyclohexylpropyl]-3α,4-dimethylpiperidine-4α-yl]phenol Preparation Products And Raw materials |
|